S1800A (immunotherapy trial)
GPTKB entity
Statements (15)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:clinical_trial
|
| gptkbp:contrastsWith |
ramucirumab plus pembrolizumab
standard of care immunotherapy |
| gptkbp:endPoint |
overall survival
|
| gptkbp:enrollment |
approximately 130 patients
|
| gptkbp:focusesOn |
immunotherapy
|
| https://www.w3.org/2000/01/rdf-schema#label |
S1800A (immunotherapy trial)
|
| gptkbp:location |
gptkb:United_States
|
| gptkbp:number |
NCT03963004
|
| gptkbp:sponsor |
gptkb:SWOG_Cancer_Research_Network
|
| gptkbp:startYear |
2019
|
| gptkbp:studies |
advanced non-small cell lung cancer
|
| gptkbp:studyType |
Phase II clinical trial
|
| gptkbp:bfsParent |
gptkb:SWOG_Cancer_Research_Network
|
| gptkbp:bfsLayer |
7
|